Boceprevir: Phase III data

The double-blind, international Phase III HCV SPRINT-2 trial in 1,097 treatment-naïve patients with chronic HCV genotype 1 infection showed that both regimens of boceprevir plus PegIntron peginterferon alfa-2b and Rebetol ribavirin met the primary endpoint

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE